SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Emcure Pharmaceuticals informs about newspaper publication

23 Nov 2024 Evaluate
Pursuant to Regulation 30 read with Para A of Part A of Schedule III and Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulation, 2015, Emcure Pharmaceuticals has enclosed copies of newspaper advertisement published in ‘Financial Express’- all editions (English) and ‘Loksatta’- Pune edition (Marathi) today i.e. Saturday, November 23, 2024, confirming completion of electronic dispatch of Notice of Postal Ballot dated November 07, 2024 and other necessary information on November 22, 2024. The above-mentioned copies of newspaper advertisement are also being uploaded on the website of the Company i.e. https://www.emcure.com.

The above information is a part of company’s filings submitted to BSE.

Emcure Pharma Share Price

1670.25 31.85 (1.94%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×